; Skip to Main Content


Skip Nav Destination

Bleeding Disorders

December 20, 2021

A collection of features and news articles published in ASH Clinical News related to bleeding disorders.


Untreated Bleeds Add to Disease Burden in Hemophilia A

In many studies of hemophilia A, only treated bleeds are reported. However, a significant proportion of bleeding events go untreated in this patient population...

Pregnancy Does Not Increase Risk of Severe Bleeding in ITP

To assess whether pregnancy was associated with worsened ITP or the incidence of neonatal ITP (NITP), researchers prospectively studied 131 pregnant women with ITP matched with 131 non-pregnant women with ITP...

Caplacizumab Reduces Exacerbations and Refractoriness in Real-World iTTP

Treatment with caplacizumab was associated with significant reductions in exacerbations and refractoriness in a real-world immune thrombotic thrombocytopenic purpura population compared with...

rFVIIIFc and rFIXFc Support Perioperative Hemostasis Management in Patients With Hemophilia

The use of extended half-life factor replacement recombinant factor VIII-Fc (rFVIIIFc) and factor IX-Fc (rFIXFc) fusion proteins was effective for managing hemostasis during...

Patient Race Linked to Relapse Risk and Rituximab Response in iTTP

Racial disparities in treatment outcomes have not been thoroughly explored despite Black patients making up the majority of iTTP cohorts. To analyze iTTP survival and relapse in relation to race, researchers conducted a multicenter study ...

Small Study Suggests Subcutaneous Rondoraptivon Pegol Improves VWF/FVIII Levels in Type 2B VWD

Treatment with the pegylated aptamer rondoraptivon pegol significantly improved levels of von Willebrand factor (VWF)/factor VIII (FVIII), multimer patterns, and thrombocytopenia in patients with type 2B von Willebrand disease (VWD), according to findings from a small phase II study...

Hemostatic Function Restored With Recombinant Porcine FVIII in Congenital Hemophilia A Samples

Porcine FVIII has been used in patients with hemophilia A and human FVIII inhibitors and was shown to be similar enough to achieve hemostatic functions of the human protein ...

Thromboelastography: Measuring Blood Coagulation in Real Time

The development of thromboelastography (TEG) in 1948 is credited to Dr. Helmut Hartert, who was working at the University of Heidelberg in Germany at the time. Also called a “viscoelastic assay,” this non-invasive test ...

Prophylactic TXA Does Not Prevent Bleeding in Thrombocytopenia From Hematologic Malignancy Treatment

Prophylactic tranexamic acid (TXA) did not decrease World Health Organization (WHO) grade ≥2 bleeding incidence or rates of platelet or red blood cell (RBC) transfusions in patients with thrombocytopenia ...

Switching to Nonacog Beta Pegol Reduces Bleeding Rates in Patients With Hemophilia B

Patients with hemophilia B who switched from recombinant factor IX-Fc-fusion protein (rFIXFc) or standard half-life (SHL) recombinant factor IX (rFIX) to nonacog beta pegol (N9-GP) experienced lower annualized rates of bleeding and reduced factor consumption ...




Connect with us:

Mid-January 2023


Close Modal

or Create an Account

Close Modal
Close Modal